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ABSTRACT 
Objective: Preparation and characterization of inhalable taste masked microparticles (MPs) loaded with the anti-asthmatic bitter drug, ketotifen 
(KT).  
Methods: MPs were prepared by a spray-drying technique. The effects of addition of different excipients namely: mannitol, leucine and hyaluronic 
acid (HA) on the physicochemical properties of KT spray dried powders were determined. Powder taste was evaluated on volunteers. DSC and x-ray 
diffraction were done to investigate thermal and crystallographic properties of the powders. The surface morphology and shape of KT-loaded 
hyaluronic acid MPs were examined using scanning electron microscope, in vitro pulmonary deposition and inhalation indices were determined 
using a twin stage glass impinger (TSI).  
Results: Leucine improved the powder flow properties. Mannitol, at all tested ratios, produced brownish discoloration in spray dried powders 
(SDP) upon storage even in dessicator. At a drug to HA ratio of 1:2, the bitter taste of KT had significantly improved besides obtaining a high 
respirable particle fraction. This selected ratio showed good physicochemical stability for up to 9 mo. 
Conclusion: The developed KT spray dried particles may offer a good platform for the targeted pulmonary delivery of the drug overcoming the 
major biological barriers. 
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INTRODUCTION 
The pulmonary system provides a non-invasive route that can be 
used to target drugs to the lungs for either local or systemic effect, 
owing to its enormous absorptive surface area (35–140 m2) lined 
with a thin (0.2 μm) and highly vascularized epithelium[1]. As a local 
lung disorder, allergic asthma represents an important public health 
issue, with significant annual growth, causing substantial morbidity 
for individuals at all ages [2, 3]. It is manifested as a chronic 
inflammatory disease with intermittent symptoms of a cough, 
dyspnea, wheezing and chest pain. Among the proposed treatment, 
ketotifen (KT), histamine H1-receptor antagonist, had been lately 
indicated for long periods [4, 5] reaching three months, especially 
for children. KT acts by inhibiting the release of mediators (e. g. 
histamine, leukotrienes, prostaglandins and platelet activation 
factor) from cells involved in immediate type I allergic reactions 
(mast cells, eosinophils, basophils and neutrophils). It also decreases 
chemotaxis, activation and degranulation of eosinophils. Increased 
cyclic adenosine monophosphate (cAMP) levels by phospho-
diesterase inhibition may contribute to KT cell stabilizing effect [6]. 
A high hepatic first-pass effect leading to low bioavailability (50%) 
with systemic side effects including trouble sleeping and flu-like 
symptoms constitute some of the major disadvantages associated with 
the administration of the oral tablets/syrup, the only marketed dosage 
forms for KT [7, 8]. By developing targeted pulmonary delivery system 
of KT, increased receptor occupancy, improved therapeutic benefits at 
lower doses with probable the decrease of systemic side effects could 
be achieved [9]. 
The cornerstone in pulmonary drug delivery is to ensure that drug 
reaches the desired site of action, which mainly depends on device 
selection and characteristics of the inhaled systems. Among the 
different pulmonary drug delivery systems, dry powder platforms 
combine both powder technology and device design to disperse dry 
particles as an aerosol during the patient’s inspiration. Accuracy, 
ease of use, physicochemical stability and of the drug and 
formulation with environmental acceptability are among the most 
common positive features of dry microparticulate compared to 
liquid-based systems [10]. In designing microparticles (MPs) for 
pulmonary delivery, the mass median aerodynamic diameter 
(MMAD), is one of the most important particle features that should 
be controlled. In this context, small particles with MMAD in the 
range of 2-5 µm are usually preferred as they deposit deeply in the 
alveolar region by sedimentation under the effect of gravity while 
particles larger than 5 µm usually impact in the upper respiratory 
tract [11]. The MMAD is generally tailored by tuning particle size 
(PS), shape and density [12,  13]. 
Unfortunately, when the particles reach the alveolar region, particles 
are rapidly engulfed, digested and migrate with macrophages up and 
out of the respiratory tract, either along the mucociliary escalator or 
entering the lymphatic system [14]. To overcome such powerful 
barrier, different formulation strategies have been adopted. For 
instance, physical camouflage based on PS as the use of nano in MPs, 
large porous particles or rapidly dissolving particles [15]and 
chemical camouflage based on modification in the surface chemistry 
to limit the negative effect of this small PS [16, 17]. To achieve the 
required size, density and surface characteristics required for 
effective lung targeting, a single step spray drying method had been 
shown great success. The use of carriers and surface modifiers was 
one of the key for the success characteristics for the success of this 
method [18].  
In designing spray dried powder (SDP) for KT, a special concern 
should be given to its well-known previously reported bitter taste 
[19]. When delivered as DPI, this taste might compromise the 
patient acceptability leading to treatment failure. So, besides the 
selection of suitable excipients for the proper lung targeting of KT, 
manipulating its taste using excipients and carriers was one of the 
primary targets. Mannitol is an example of sugars that had been used 
for protecting the powders from the high temperatures and fast 
moisture removal encountered during spray drying [20]. Due to its 
excellent dispensability enhancer properties, leucine had also been 
used in this study [21]. Hyaluronic acid (HA) is a natural linear 
polysaccharide comprised of repeating units of D-glucuronic acid 
and N-acetyl–D-glucosamine[22] as shown in fig.1. 
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Fig. 1: Hyaluronic acid chemical structure 
 
It is biodegradable, biocompatible, non-toxic, non-immunogenic and 
non-inflammatory that has been used in various medical 
applications including arthritis treatment, wound healing, ocular 
surgery, and tissue augmentation [23]. Due to its mucoadhesive 
activity, it may prolong time contact time MPs remain close to the 
main absorption site in the deep lung. HA is naturally present in lung 
and is responsible for protecting lung elastin from the damage 
associated with inflammatory diseases and involved in the repair of 
lung injury. As an endogenous lung component, it inhibited 
phagocytosis in a dose and molecular weight-dependent manner 
[24]. Recently, HA was shown to have specific anti-asthmatic 
properties and to be an effective treatment for emphysema and 
chronic obstructive pulmonary disease (COPD) [25]. 
Accordingly, the ultimate goal of this work was to develop KT loaded 
spray dried powder (SDP) for pulmonary administration. The effects 
of the chosen excipients on the physicochemical characteristics 
including taste, in vitro release and stability, were investigated. In 
vitro pulmonary deposition was characterized using a twin stage 
impinger (TSI). 
MATERIALS AND METHODS 
Materials 
Ketotifen hydrogen fumarate (KT): a kind gift from Novartis, Cairo, 
Egypt; L-leucine (LEU), purchased from Fluka, Switzerland; 
mannitol: from El Nasr Pharmaceutical Chemicals (ADWIC), Abo 
Zaabal, Cairo, Egypt and hyaluronic acid (Mw= 1.36 M Da): a kind 
gift from Bloomage Freda Biopharm Co., Jinan, China. 
Methods 
Microparticles preparation by spray drying 
A primary excipient screening study was first conducted. KT and 
other excipients were dissolved, each individually, in water then 
mixed together. The prepared solutions containing 1% w/v total 
solid were spray dried using a mini spray dryer (Buchi B-290, 
Switzerland) applying the following parameters: inlet temperature: 
120 ᵒC, aspiration rate: 85% and the pump flow rate: 4%. The 
resultant outlet temperature was 74±2 ᵒC. Table 1 shows the 
composition of the prepared formulae. For the preparation of KT-
loaded HAMPs, different concentrations of HA and KT, at a different 
drug to polymer ratios (D/P), were dissolved in deionized water. 
The solutions were magnetically stirred for 30 min and leucine was 
added in a concentration of 10% w/w of the spray dried powder. 
 
Table 1: Composition of KT loaded spray dried formulae 
Formula code Formulae composition % (w/w) 
KT Mannitol Leucine HA 
D 100 - - - 
DM 50 50 - - 
DL 50 - 50 - 
DML 50 25 25 - 
DHL1 60 - 10 30 
DHL2 45 - 10 45 




The spray drying process yield was calculated gravimetrically by 
comparing the amount of powder resulting following spray drying 
with the initial theoretical total solids [26]. 
Drug content determination 
Drug content was determined and the drug association efficiency 
percentage (AE%) in the spray dried powder (SDP) was calculated 
by comparing the actual with theoretical drug loading values as 
follow: an accurately weighed amount (10 mg) of each SDP was 
added to 2 ml water and then stirred for 15 min at room 
temperature. After proper dilution, the drug content was 
determined by UV spectrophotometry at the predetermined λmax 
(300 nm). KT AE%, theoretical and actual loading were calculated 
using equations 1-3. 
KT AE% = Actual KT amount
Theoritical KT amount
× 100 …………………………………. Eq.1 
Theoretical KT loading capacity = Theoretical KT amount
Powder weight
× 100…Eq. 2 
Actual KT loading capacity = Actual KT amount
Powder weight
× 100………………. Eq. 3 
 
Powder flow properties 
The static angle of repose (Ө) was determined by adopting the fixed 
height cone method. In this method, a glass funnel with an internal 
diameter of 5 mm was tightened at 1 cm height. The SDP was allowed 
to flow at a constant rate through the funnel orifice till the apex of the 
formed cone reached the funnel stem. The powder flow was stopped 
and the diameter of the base of the formed cone was measured. The 
angle of repose was calculated as follows in equation 4. 
Tan Ө = 2H/D…………………Equation 4 
Where: Ө is the angle of repose, H is the height of the cone and D is 
the diameter of the base of the formed cone. The test was repeated 
five times for each run and the average value was taken. Values for 
the angle of repose below 25 indicate excellent flow, 25-30 good 
flow, and 30-40 passable flow while those above 40 denote very 
poor flow [27, 28]. 
Taste evaluation 
The taste of the SDP was evaluated in a panel of 5 volunteers using a 
score of 5. A score of 5 was given to a SDP consisting of the drug 
alone denoting very bitter taste. Improvement of the taste was 
characterized by a decrease in this score [29]. 
Particle size (PS) determination and calculation of mass median 
aerodynamic diameter (MMAD) 
PS was measured by the wet dispersion method (Laser diffraction PS 
analyzer Malvern MasterSizer S, UK). A small amount (2-3 mg) of 
each of each SDP was suspended in isopropanol as an anti-solvent, 
sonicated for 30 seconds and PS was measured. The observed 
average PS was expressed as volume mean diameter (VMD) and the 
population dispersity was referred as span. D[v,10], D[v,50],D[v,90] 
and D[4,3] are the respective diameters at 10,50, 90 and the volume 
mean diameter in µm respectively and the SPAN values were also 
noted. The mass median aerodynamic diameter (MMAD) was then 
calculated as follow in equation 5. 
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MMAD = dg �
ρ
ρa
 …………………. Equation 5 
Where ρ is the mass density of the particle (tapped density), ρa is the 
unit density (1g/cm3) and dg is the cumulative geometric volume 
mean diameter [30, 31]. For density determination, a certain weight 
of each SDP was introduced into a small volumetric cylinder; the 
cylinder was tapped several times (about 50 times) on a solid 
surface till constant volume and the new volume occupied by the 
powder was recorded (tapped volume). Tapped density was 
calculated as shown in equation 6. 
Tapped density =powder weight
Tapped volume
……………. Equation 6 
Thermogravimetric analysis (TGA) 
The water content of SDP formulations was examined by 
Thermogravimetric analyzer (Perkin Elmer, Pyris I-Wellesley, USA). 
Samples of 3-5 mg of SDP were heated to 150 ᵒC under nitrogen 
purging, at a constant heating rate of 10ᵒC/min. The percent weight 
loss was calculated as its water content was evaporated and defined 
as the moisture content. It was expressed as percent of the initial 
powder weight. 
In vitro pulmonary deposition 
Aerodynamic properties were tested using a dry powder, breath-
activated inhaler device (Aerolizer®, Novartis) [32]. Volumes of 7 and 
30 ml of the collecting solvent (water) were introduced into the 
upper and lower chamber of the TSI (Copley Scientific Ltd, UK), 
respectively. An amount of 10 mg of each selected SDP was loaded in 
hard gelatin capsule No. 3 which was placed in the Aerolizer® 
attached to the throat of the impinger. The capsule was pierced to 
produce two emitting pores for dispersing the particles, and the 
powder was drawn through the TSI at an air flow rate of 60 L/min, 
using an electronic digital flow meter, for 2x 5 seconds aspirations. 
After actuation, the capsule was removed and the weight of the drug 
remained in the capsule was determined. Powder remaining in the 
capsule and mouthpiece of the device was collected by rinsing with 
the collecting solvent to a volume of 10 ml and evaluated for drug 
content. The deposits at stages 1 and 2 were collected and then 
diluted to appropriate volumes (25 and 50 ml respectively). Drug 
content of the powder collected on each stage was determined by 
measuring the absorbance of the solution at 300 nm. Each 
deposition experiment was performed in triplicate. The particles 
captured in lower impinger stage are termed the respirable particle 
fraction (RP) and are expected to be deposited in the deep lung after 
inhalation. The in vitro aerodynamic aerosolization properties of the 
powders were described in terms of The emitted fraction (EF) 
defined as the percent of total loaded powder mass exiting the 
capsule[26] and was determined gravimetrically and can be 
expressed as shown in equation 7. 
EF = (mfull−mempty)/mpowderx 100. . Equation 7 
Where mfull and mempty are the masses of the capsule before and after 
simulating the inhalation respectively, and mpowder is the mass of the 
powder. Two other indices, the respirable particle fraction (RP) 
which is a percentage of stage 2 against emitted particles from the 
inhalation system and the effective inhalation index (EI), were also 
calculated using equations 8 and 9 [33]. 
RP %= (St2/EF) x 100……………. Equation 8 
EI % = (EF xSt2) ½…………………. Equation 9 
Where EF is the fraction (%) emitted from the inhalation system and 
St2 is the fraction (%) distributed to stage 2 of the TSI. For an ideal 
DPI, the EI and RP are 100%. 
In vitro release study 
An accurately weighed amount of selected SDP equivalent to 1 mg 
KT was added to 4 ml of 0.05M phosphate buffer solution (PBS), pH 
7.4, in closed containers. The samples were incubated in a shaking 
water bath rotating at 100 strokes/min adjusted at 37±0.5 ᵒC. This 
volume provided complete sink conditions for KT [6]. At specified 
time intervals, (2, 5 and 15 min); samples were withdrawn, replaced 
by the fresh buffer to maintain sink conditions, centrifuged and the 
supernatants were assayed spectrophotometrically at 
predetermined λmax to determine the concentration of KT. All the 
results were the mean values of three runs. 
X-ray power diffraction (XRPD) 
XRPD was used to determine the presence of crystalline and 
amorphous content in the selected SDP formulations. X-ray 
diffractometer (Philips, Guildford, UK) running at 45 kV, 30 mA, and 
at scanning angles of 5-45ᵒ was used to analyze the samples.  
Differential scanning calorimetry (DSC) 
The thermal properties of KT, HA, leucine, KT: HA: leucine physical 
mixture (1:1:1) and selected SDP were investigated, using 
differential scanning calorimeter (DSC) (Shimadzu, Tokyo, Japan). 
An accurately measured amount of each sample (3-5 mg) was sealed 
in an aluminum pan with a lid and was heated at a rate of 10ᵒC/min 
to a temperature 400ᵒC, using dry nitrogen as carrier gas at a flow 
rate of 30 ml/min [26]. 
Scanning electron microscope (SEM) 
The morphological examination was performed using SEM 
(Stereoscam 90B, UK). SEM was used to examine shape and surface 
characteristics of selected SDP. The particle surface of SDP was 
vacuum coated with a gold film to a thickness of 200-500ᵒA under an 
argon atmosphere in sputter couture prior to SEM analysis, and then 
the particles were visualized at 20 kV acceleration voltages and 
images were obtained. 
Stability study 
The effect of storage on selected formulation was evaluated by 
determination of the PS after storing the formula for three, six and 
nine months in closed desiccator containing silica gel and stored at 
room temperature (25±2 °C). 
Statistical analysis 
All data are expressed as the mean of three determinations± 
standard deviations (sd). The experimental data was analyzed 
statistically using Graph Pad Prism program by which either the 
student’s t test (when comparing the mean of two groups) or by 
analysis of variance (ANOVA, for more than two groups). Differences 
were considered significant at p ≤0.05. 
RESULTS AND DISCUSSION 
Spray dried powder characteristics 
In this work, KT loaded SDP were developed. The effect of the 
excipients on the powders characteristics was first investigated. 
Table 2 shows that 57±2.45% of drug amount were recovered 
following its spray drying alone without any additive. The obtained 
SDP tended to form clumps and aggregates following spray drying 
and storage in desiccators. These aggregation might be the result of 
fast moisture removal during spray drying leading to a highly 
hygroscopic product as also noted in other previous studies [34]. 
The addition of mannitol in a concentration of 50% did not cause 
any significant change in powder yield or angle of repose. 
Conversely, 50%w/w of leucine (in DL) caused a significant increase 
in powder yield which reached 86±2.76% with a decrease in angle of 
repose denoting improvement of flow. The increase in yield in DML 
containing 25% leucine was lower (75±1.78%). Noteworthy to 
mention that a brownish color with the formation of some clumps 
and aggregates were noticed in DM within two days of storage in 
desiccators. This brownish coloration occurred probably due to the 
presence of traces of reducing sugars produced from catalytic or 
electrolytic reduction of monosaccharides such as mannose or 
glucose in mannitol. The major chemical interaction associated with 
the reducing sugars impurities is Millard reaction with amine drugs 
[35]. Similarly, there was a brownish discoloration in formula DML 
after one-month storage in desiccator due to the presence of 
25%w/w mannitol. The effect of leucine in improving SDP yield and 
flow properties had been reported in previous literature [36]. 
Irrespective of the used excipients, high association efficiencies, 
exceeding 90% were achieved with all formulae. 
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Due to the previously reported bitter taste of KT [19] and the 
intended delivery as DPI with the possibility of some oropharyngeal 
deposition, it deemed necessary to evaluate the taste of the prepared 
formulae. The presence of mannitol and/or leucine caused a slight 
improvement of the taste. The sweet taste and negative heat of 
solution of the sugar mannitol and the precipitation of the low-
density surfactant, leucine, on the surface of evaporating droplet 
contributed to the drug taste masking [37]. However, the 
improvement in taste was not enough to allow for patient 
compliance during drug administration. Hence, the use of HA, 
previously shown to improve the tolerability of hypertonic saline 
used in treating cystic fibrosis patients by giving a pleasant taste in 
mouth after inhalation, was tried [38, 39]. 
Due to its impact on the flow and yield values, leucine was 
incorporated in KT/HA formulae as 10% w/w. As shown in table2, 
low yield amounting of51.87±6.17% was obtained at D/P of 2:1 D/P. 
The yield increased significantly with increasing the concentration 
of HA to 76.49±2.63and91.70±3.65 in DHL2 and DHL3, respectively. 
The corresponding decrease in KT amounts accounts for such 
increase in yield. High association efficiencies (AE %) exceeding 
94% were achieved with all formulae containing HA at different D/P 
ratios. The assayed KT contents were very close to the theoretical 
values confirming that only small amounts of KT were lost during 
spray drying process.  
The highest angle of repose was noted with DHL1 prepared at the 
highest KT loading (D/P ratio of 2:1) denoting poor flow. This 
observation probably supported the observed low yield obtained at 
this D/P ratio. As the amount of HA increased, there was a significant 
decrease in angle of repose till D/P ratio of 1:2 (formula DHL3) 
explaining the obtained yield value. It is to be noted that it was only 
at a theoretical KT loading of 30% that the taste of the SDP showed 
the maximum taste improvement achieving a score of 1. To this end, 
2 formulae, namely DL and DHL3, were chosen for PS measurement, 
MMAD determination, TGA and in vitro pulmonary deposition. 
 
Table 2: Characteristics of KT spray dried powder formulae. 
Formula code Yield (%) AE (%) KT loading (%w/w) Angle of repose(Ө) Taste score 
Theoretical Actual 
D 57±2.45 - 100 - 49.89±0.90 5 
DM 60±2.67 94.74±1.76 50 47.58±1.47 48.78±1.32 2 
DL 86±2.76 98.74±2.56 50 49.95±2.65 39.43±0.65 2 
DML 75±1.78 95.66±2.23 50 48.36±1.83 46.65±1.54 2 
DHL1 51.87±6.17 97.12±5.67 60 58.94±2.34 46.90±0.60 4 
DHL2 76.49±2.63 96.34±6.78 45 44.32±1.34 44.49±0.66 2 
DHL3 91.70±3.65 95.67±5.32 30 28.57±1.43 39.66±1.48 1 
*Results are mean of three determinations±sd. 
 
Table 3 showing the size, density and MMAD of the chosen formulae 
show that 90% of the particles were less than 5 μm. Due to the low 
density of the particles, the calculated MMAD was found to be lower 
than their determined geometric PS where DL and DHL3 were found 
to be 1.37±0.05 and 1.42±0.16 respectively indicating suitability for 
deep lung deposition following inhalation [40]. 
 
Table 3: PS, tapped density and MMAD of selected KT loaded spray dried formulae 
Code D[4,3]a Span Tapped density 
(g/cm3) 
Distribution percentile volume (µm) MMADb (µm) 
10% 50% 90% 
DL 2.87±0.54 1.78±0.04 0.23±0.02 0.79±0.05 3.78±0.12 4.78±0.23 1.37±0.05 
DHL3 2.75±0.46 2.12±0.12 0.27±0.03 0.58±0.07 2.99±0.07 4.86±0.17 1.42±0.16 
Results are mean of three determinations±sd. aD[4,3]: volume means diameter andb MMAD: mass median aerodynamic diameter. 
 
 
Fig. 2: TGA charts of formulae: (a) DHL3 and (b) DL 
 
Thermogravimetric analysis (TGA) 
As shown in fig. 2, the higher residual moisture of 2.42% was found 
in DHL3 compared to DL (1.65%) probably due to the presence of 
HA with its water retaining ability. Obviously, the selected spray 
drying parameters were suitable to produce dried powder with a 
minimal moisture content not exceeding the allowed limits [41]. 
In vitro pulmonary deposition 
ATSI was used to describe the powder inhalation properties of 
formulae DL and DHL3. The drug deposited at the various stages of 
the impinger is illustrated in fig. 3. The inhalation indices namely EF, 
RP and EI were calculated and are presented in table 4. Lower 
mouth, similar stage 1andhigher stage 2 depositions were obtained 
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with DHL3 compared to DL. In spite of this difference, the calculated 
inhalation indices, EF% and RP%, were high and did not vary 
significantly among the 2 tested formulae while a higher EI% of 
73.04±1.99 was obtained with DHL3 as seen in table 4. 
 
 
Fig. 3: in vitro pulmonary deposition of KT spray dried formulae using TSI 
 
Table 4: Inhalation indices of KT-loaded HA spray dried formula 
Formula code Inhalation indices (%) 
EF% RP% EI % 
DL 87.5±1.55 77.47±2.80 66.17±1.60 
DHL3 90.33±2.51 80.30±2.33 73.04±1.99 
Results are means of three determinations±sd, ED: emitted fraction, RP: respirable particle fraction and EI: effective inhalation index. 
 
In vitro release study 
Fig.4 shows that KT powder as received dissolved at a fast rate 
releasing 95% of the drug in 5 min. The same release pattern 
occurred with formulae DHL3and DL where 100% release was 
achieved in less than 15 min. the presence of HA with its carboxyl 
and hydroxyl groups did not retard the drug release [42, 43]. 
Achieving complete drug dissolution in a short time will help to 
avoid uptake of MPs by the macrophages freely roaming in the 
alveolar region. 
Based on the criteria of attaining a formula with the lowest taste 
score, highest inhalation indices, formula DHL3 prepared at a 
theoretical drug loading of 30 % w/w was selected for further 




Fig. 4: In vitro release of KT-SD formulae in 0.05M phosphate buffer solution (pH 7.4) at 37ᵒC and 100 stroke/min (mean±sd, n=3) 
*For formulae composition, refer to table 1. 
 
X-ray powder diffraction 
Crystallographic structure of KT, HA, leucine and selected 
formula DHL3 were determined by X-ray powder diffraction 
(XRPD) and are presented in fig.5. In accordance with the 
literature, the diffractograms of pure KT exhibited a series of 
intense peaks denoting its crystalline structure as shown in 
fig.5(a) [44]. HA as a polymer had an amorphous pattern as 
shown in fig.5(b). The diffractogram of leucine, fig. 5(c), shows 
characteristic peaks at 5ᶱ, 25ᶱ and 31ᶱ indicating high 
crystallinity.  
Examination of the diffractogram of formula DHL3 revealed that 
it exhibited none of the drug sharp crystal peaks as shown in fig. 
5(d) and indicating drug amorphization within the polymeric 
matrix.  
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Fig. 5: X-ray diffractograms of pure (a) ketotifen hydrogen fumarate, (b) hyaluronic acid, (c) leucine and (d) selected formula DHL3 
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Differential scanning calorimetry (DSC) 
Thermal analysis is a very useful technique for evaluating the 
influence of excipients and spray drying process on the 
physicochemical properties of the materials and dosage forms. The 
thermal properties of KT, HA, leucine, their physical mixture (1:1:1) 
and selected formula DHL3 were investigated using DSC. Pure KT 
thermogram, shown in fig.6(a), revealed a single sharp endothermic 
peak showing maximum at 200ᵒC corresponding to its melting 
temperature [45]. The thermogram of HA, fig. 6(b), shows a 
characteristic endothermic peak at 90ᵒC correlated with loss of 
water associated to the polymer hydrophilic groups and a higher 
exothermic peak at 241ᵒC resulting probably from polymer 
decomposition [46]. Leucine, fig. 6(c),did not show any 
characteristic peak at the temperature range used in this study [47].  
DSC thermogram of KT: HA: leucine physical mixture was a simple 
superposition of peaks of the individual components as shown in fig. 
6(d). On the other hand, KT typical melting endotherm was almost 
absent in thermogram of DHL3 as shown in fig. 6(e). Only a very 
small endotherm corresponding probably to the presence of minute 
drug crystals confirming drug excipient compatibility could be seen 
in DHL3 thermogram. These minute crystals might be buried inside 
the matrix and that is why they could not be detected by XRPD. 
 
 
Fig. 6: DSC of(a) ketotifen hydrogen fumarate, (b) hyaluronic acid, (c) leucine, (d) physical mixture of 1:1:1 (KT: HA: leucine) and (e) 
selected spray dried formula DHL3 
 
Scanning electron microscope (SEM) 
SEM images of DHL3, shown in fig.7, reveal non-aggregated 
collapsed MPs with dented surfaces. The observed PS was in 
accordance with the results obtained with laser diffraction data. The 
presence of leucine prevented fusion and sintering between adjacent 
MPs [48]. Also, no drug crystals could be seen in the micrographs of 
HA microspheres. 
Stability study 
One of the major problems encountered following the spray drying 
is the agglomeration and fusion of the particles during storage. This 
is very critical for powders intended for pulmonary administration. 
To guarantee the stability of the selected SDP formula DHL3, the PS 
was evaluated after 3, 6 and 9 mo of storage at room temperature in 
a dessicator. As shown in table 5, no significant change was noticed 
in the PS confirming the stability of the selected SDP under ambient 
conditions. Moreover, no visible agglomeration was seen reflecting 
the suitability of the selected excipients. 
 
 
Fig. 7: SEM image of KT loaded spray dried powder (formula 
DHL3)




Freshly prepared After 3 mo After 6 mo After 9 mo 
DHL3 2.75±0.46 2.76±0.57 2.85±0.67 2.91±0.10 
DL 2.87±0.54 2.89±0.23 2.91±0.65 2.98±0.32 
All results are expressed as the mean of 3 determinations±sd, aPS measured by laser diffraction. 
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In this study, KT loaded spray dried powders targeting the 
pulmonary tract was developed. Leucine improved the flow ability of 
the SDP. A brown discoloration was shown in all formulae 
containing mannitol. The best inhalation indices, best bitter taste 
masking with PS suitable for inhalation were seen at a HA: drug ratio 
of 1:2. DSC and X-ray diffraction studies showed complete 
amorphization of KT inside the polymeric matrix. SEM images 
revealed non-aggregated dented surfaces. Immediate dissolution of 
the SDP will help in avoiding uptake of MPs by the roaming alveolar 
macrophages. 
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